Cite
HARVARD Citation
Ellingson, B. et al. (2018). Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-oncology. 20 (10), pp. 1411-1418. [Online].